Literature DB >> 21564276

Clinical and echocardiographic correlates of plasma B-type natriuretic peptide levels in patients with aortic valve stenosis and normal left ventricular ejection fraction.

Sylvestre Maréchaux1, Mehdi Hattabi, Francis Juthier, Dan Valentin Neicu, Marjorie Richardson, Emilie Carpentier, Nadia Bouabdallaoui, François Delelis, Carlo Banfi, Joke Breyne, Brigitte Jude, Philippe Asseman, André Vincentelli, Thierry Le Tourneau, Pierre Graux, Philippe Pibarot, Pierre Vladimir Ennezat.   

Abstract

BACKGROUND: Several studies suggest that BNP testing may help define the timing of aortic valve surgery in patients with aortic valve stenosis (AVS) prior onset of overt LV systolic dysfunction. The aim of this study was to identify clinical and echocardiographic correlates of plasma BNP levels in a large cohort of patients with AVS and preserved LV ejection fraction. METHOD AND
RESULTS: One hundred thirty-five consecutive patients were prospectively included in the present study (Mean age 73 ± 13 years old, 66 (49%) male). Eighty-nine patients (66%) had severe AVS (aortic valve area <0.6 cm(2) /m(2) BSA). Plasma BNP levels, clinical and comprehensive Doppler echocardiography evaluation was performed in all patients. Independent clinical correlates of plasma BNP levels (R(2) = 0.19) were older age (P < 0.0001) and presence of AVS symptoms (P = 0.004). Independent echocardiographic correlates of plasma BNP levels (R(2) = 0.38) were E/Ea ratio (P = 0.01), LV mass index (P = 0.018), left atrial surface (P < 0.0001) and systolic pulmonary artery pressure (sPAP; P = 0.004). Overall, independent correlates of plasma BNP levels (R(2) = 0.47) were older age (P = 0.001), known coronary artery disease (P = 0.047), increased LV mass index (P = 0.001), left atrial enlargement (P = 0.002), and increased sPAP (P = 0.003).
CONCLUSIONS: In patients with AVS and normal LV ejection fraction, plasma BNP predominantly reflects the clinical and echocardiographic consequences of afterload burden imposed on the left ventricle rather than the severity of valve stenosis, per se.
© 2011, Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21564276     DOI: 10.1111/j.1540-8175.2011.01418.x

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  3 in total

1.  Comparison of transesophageal echocardiographic analysis and circulating biomarker expression profile in calcific aortic valve disease.

Authors:  Rachana Sainger; Juan B Grau; Emanuela Branchetti; Paolo Poggio; Eric Lai; Erblina Koka; William J Vernick; Robert C Gorman; Joseph E Bavaria; Giovanni Ferrari
Journal:  J Heart Valve Dis       Date:  2013-03

2.  Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study.

Authors:  Gholamhossein Alishiri; Kiyan Heshmat-Ghahdarijani; Mohammad Hashemi; Reihaneh Zavar; Maryam Moshkani Farahani
Journal:  J Res Med Sci       Date:  2020-06-30       Impact factor: 1.852

3.  Impact of underlying heart disease per se on the utility of preoperative NT-proBNP in adult cardiac surgery.

Authors:  Huiqi Jiang; Henrik Hultkvist; Jonas Holm; Farkas Vanky; Yanqi Yang; Rolf Svedjeholm
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.